AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
ImmunityBio 2025 Q3 Earnings Revenue Surges 433.8% as Net Loss Narrows by 21.5%
Generated by AI AgentDaily EarningsReviewed byAInvest News Editorial Team
Thursday, Nov 6, 2025 4:47 pm ET1min read
Aime SummaryImmunityBio (NASDAQ: IBRX) reported Q3 2025 earnings on Nov 6, 2025, showcasing a 433.8% year-over-year revenue surge to $31.78 million, driven by strong demand for its flagship product, ANKTIVA. , a 21.5% improvement from $85.75 million in Q3 2024. Despite the revenue growth, persistent R&D and SG&A expenses kept the company unprofitable, .
Revenue
Product revenue, net, , contributing to a total revenue of $32.06 million, . This 433.8% year-over-year growth reflects robust adoption of ANKTIVA in bladder cancer treatment and expanding market access.
Earnings/Net Income
, , . Despite these gains, sustained losses over 12 consecutive quarters underscore the need for further cost optimization and revenue diversification to achieve profitability.
Post-Earnings Price Action Review
Following the earnings release, , with a 10.17% drop over the past week and a 15.20% monthly slump. The mixed performance reflects investor skepticism about the company’s path to profitability, despite revenue momentum and clinical progress.
Additional News
UK MHRA Approval:
secured UK approval for ANKTIVA in bladder cancer treatment, marking its first international authorization.Clinical Trial Advances: Promising data from glioblastoma and NSCLC trials, including 100% disease control in 5 GBM patients, reinforced ANKTIVA’s therapeutic potential.
Shareholder Reforms: A court-approved settlement added an independent director to ImmunityBio’s board, addressing governance concerns and strengthening investor confidence.
Daily Earnings
Get noticed about the list of notable companies` earning reports after markets close today and before markets open tomorrow.
Latest Articles
Brown-Forman A 2026 Q2 Earnings Revenue Falls 5.4%, Net Income Drops 13.2%
Dec.05 2025
Argan 2026 Q3 Earnings Record Net Income and $3B Backlog Despite Revenue Dip
Dec.05 2025
John Wiley Sons B 2026 Q2 Earnings EPS Rises 13.3% Despite Revenue Decline
Dec.04 2025
John Wiley Sons A 2026 Q2 Earnings Strong EPS Growth Amid Revenue Decline
Dec.04 2025
Titan Machinery 2026 Q3 Earnings Net Income Drops 30.1% Amid Revenue Decline
Dec.04 2025
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet